Arformoterol tartrate in the treatment of COPD

References

• Celli BR, MacNee W. ATS/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J.23, 932–946 (2004).
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med.176, 532–555 (2007).
   PubMed Web of Science ®Google Scholar
• National Asthma Education Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma – summary report 2007. J. Allergy Clin. Immunol.120(5 Suppl.), S94–S138 (2007).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J.31, 143–178 (2008).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Lõtvall J. Ultra long-acting β2 agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs14, 775–783 (2005).
   PubMed Web of Science ®Google Scholar
• Ameredes BT, Calhoun WJ. (R)-albuterol for asthma: pro. Am. J. Respir. Crit. Care Med.174, 965–969 (2006).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Treatment with (R)-albuterol has no advantage over racemic albuterol. Am. J. Respir. Crit. Care Med.174, 969–972 (2006).
   PubMed Web of Science ®Google Scholar
• Kelly HW. Levalbuterol for asthma: a better treatment? Curr. Allergy Asthma Rep.7, 310–314 (2007).
   PubMed Web of Science ®Google Scholar
• Abbott MB, Levin RH, Miller JA. Point–counterpoint: a comparison of levalbuterol and racemic albuterol in the treatment of pediatric asthma. Pediatr. Rev.25, 108–109 (2004).
   PubMedGoogle Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br. J. Pharmacol.155, 291–299 (2008).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir. J.34, 757–769 (2009).
   PubMed Web of Science ®Google Scholar
• Handley DA, Senanayake CH, Dutczak W et al. Biological actions of formoterol isomers. Pulm. Pharmacol. Ther.15, 135–145 (2002).
   PubMed Web of Science ®Google Scholar
• Mhanna MJ, Koester JF, Cohn RC. Effects of (R,R)- and (R,R/S,S)-formoterol on airway relaxation and contraction in an experimental rat model. Curr. Ther. Res.68, 249–261 (2007).
   PubMed Web of Science ®Google Scholar
• Delmotte P, Sanderson MJ. Effects of formoterol on contraction and Ca2+ signaling of mouse airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol.42(3), 373–381 (2009).
   PubMed Web of Science ®Google Scholar
• Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle. J. Allergy Clin. Immunol.116, 65–72 (2005).
   PubMed Web of Science ®Google Scholar
• Steinke JW, Baramki D, Borish L. Opposing actions of (R,R)-isomers and (S,S)-isomers of formoterol on T-cell function. J. Allergy Clin. Immunol.118, 963–965 (2006).
   PubMed Web of Science ®Google Scholar
• Abraha D, Cho SH, Agrawal DK, Park JM, Oh CK. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. Int. Arch. Allergy Immunol.133, 380–388 (2004).
   PubMed Web of Science ®Google Scholar
• Cada DJ, Levien T, Baker DE. Arformoterol tartrate. Hosp. Pharm.42, 447–454 (2007).
   Google Scholar
• Brovana™, package insert. Sepracor Inc., MA, USA (2008).
   Google Scholar
• Kharidia J, Fogarty CM, Laforce CF et al. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther.21, 657–662 (2008).
   PubMed Web of Science ®Google Scholar
• Lötvall J, Palmqvist M, Ankerst J et al. The effect of formoterol over 24 h in patients with asthma: the role of enantiomers. Pulm. Pharmacol. Ther.18, 109–113 (2005).
   PubMed Web of Science ®Google Scholar
• Baumgartner RA, Mazzetti A, Claus R, McVicar W, Hanrahan JP. Crossover dose-ranging study of arformoterol in patients with COPD (abstract). Proc. Am. Thorac. Soc.3, A847 (2006).
   Google Scholar
• Panettieri RA Jr, MacIntyre N, Sims M et al. Comparison of the efficacy and safety of arformoterol 15 µg twice daily and arformoterol 30 µg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study. Clin. Ther.31, 1716–1723 (2009).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D5, 25–27 (2004).
   PubMedGoogle Scholar
• Hanania NA, Donohue JF, Nelson H et al. The safety and efficacy of arformoterol and formoterol in COPD. J. COPD (2010) (In Press).
   PubMedGoogle Scholar
• Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin. Ther.29, 261–278 (2007).
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD5, 25–34 (2008).
   PubMedGoogle Scholar
• Donohue JF, Hanania NA, Sciarappa KA et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance Ther. Adv. Respir. Dis.2, 37–48 (2008).
   PubMedGoogle Scholar
• Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. J. COPD6, 404–415 (2009).
   PubMedGoogle Scholar
• Tashkin DP, Donohue JF, Mahler DA et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med.103, 516–524 (2009).
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Grogan D, Morganroth J, Cheng H, Baumgartner R. The effect of twice-daily nebulized arformoterol on QTC in subjects with COPD (abstract). Chest132, 532–533 (2007).
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J.31, 416–469 (2008).
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Grogan DR, Baumgartner RA et al. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting β2-agonists arformoterol and salmeterol. Medicine (Baltimore)87, 319–328 (2008).
   PubMed Web of Science ®Google Scholar
• Bauer A, McGlynn P, Bovet LL, et al. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir. Care.54, 1342–1347 (2009).
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest127, 335–371 (2005).
   PubMed Web of Science ®Google Scholar
• Thorsson L, Geller D. Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide. Respir. Med.99, 836–849 (2005).
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ. Nebulized respiratory medications: friend or foe? Geriatr. Nurs.30, 45–49 (2009).
   PubMed Web of Science ®Google Scholar
• Brophy C, Kastelik JA, Gardiner E, Greenstone MA. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD. Chron. Respir. Dis.5, 13–18 (2008).
   PubMedGoogle Scholar
• Tashkin DP, Klein GL, Colman SS, Zayed H, Schonfeld WH. Comparing COPD treatment: nebulizer, metered dose inhaler, and concomitant therapy. Am. J. Med.120, 435–441 (2007).
   PubMed Web of Science ®Google Scholar
• Anonymous. Arformoterol (Brovana) for COPD. Med. Lett.49, 53–54 (2007).
   Google Scholar
• Matera MG, Cazzola M. Ultra-long-acting β2-adrenoceptor agonists. An emerging therapeutic option for asthma and COPD? Drugs67, 503–515 (2007).
   PubMed Web of Science ®Google Scholar
• Molfino NA. Drugs in clinical development for chronic obstructive pulmonary disease. Respiration72, 105–112 (2005).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir. Med.102, 479–487 (2008).
   PubMed Web of Science ®Google Scholar